Last Verified: | August/31/2019 |
First Submitted: | July/8/2019 |
Estimated Enrollment Submitted: | July/8/2019 |
First Posted: | July/11/2019 |
Last Update Submitted: | September/5/2019 |
Last Update Posted: | September/9/2019 |
Actual Study Start Date: | April/14/2015 |
Estimated Primary Completion Date: | February/6/2020 |
Estimated Study Completion Date: | December/29/2020 |
Study Type: | Interventional |
Allocation: | N/A |
Primary Purpose: | Prevention |
Masking: | None (Open Label) |
Arm | Intervention/treatment |
---|---|
Other: Booster vaccination Intervention = one i. m. TBE booster vaccination (FSME-Immun) at visit 1. | Drug: Booster vaccination Booster with TBE vaccine (i.m.) FSME Immun |
Ages Eligible for Study: | 18 Years to 18 Years |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | Yes |
Criteria: | main Inclusion Criteria: - willingness to sign written informed consent form - completed primary TBE immunization and at least 1 booster vaccination - participants of both sexes between 18 and 60 years of age main Exclusion Criteria: - age < 18 and > 60 years - BMI 25-30 - previous TBE infection - pregnancy or breast feeding - acute infection on day of inclusion (day 0) or at visit 5 (36 months), body temperature > 37,9°C - concomitant medications: systemic cortison therapy, chemotherapy, immunotherapy (allergy) immunsuppressive therapy 4 weeks prior or during the study - administration of other vaccines 4 weeks before/after day 0 - planned surgery within 2 weeks before/after TBE booster - any contraindication to administration of FSME-Immun® vaccine according to manufacturer's instructions - malignant diseases within 5 years prior to the study - autoimmune diseases - kidney insufficiency, dialysis - drug addiction - plasma donor - receipt of blood transfusions or immunoglobulins within 3 months prior to study entry / within 3 months prior to visit 5 - Severe disease with hospitalization or surgery 3 months before or during the study - participation in a clinical trial simultaneously to visit 1-4 with receipt of vaccination and/or investigational product within one month before booster |